White House in Washington D.C.

Biden-⁠Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States

ATLANTA, GA – Today, Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), has officially designated fentanyl adulterated or associated with xylazine as an emerging threat to the United States. Xylazine is a non-opioid tranquilizer approved by the Food and Drug Administration (FDA) for veterinary use but not human use. This designation comes after careful review of the impact of xylazine on the opioid crisis, including its growing role in overdose deaths in every region of the United States.

Similar Posts

  • A Horrifying Drug Called ‘Tranq Dope’ Is Spreading in the US

    The animal tranquilizer xylazine, which has been linked to severe wounds and amputations, has been detected in nearly 40 states. VICE | Manisha Krishnan November 15, 2022 After two years of sobriety, Allie Gramlich began using drugs again in April. This time around, Philadelphia’s street opioid supply was infiltrated with tranq or tranq dope, a…

  • Over-the-counter sales of Narcan to begin this week

    By Lindsey Theis The purple pinwheel in Michelle Leopold’s front yard symbolizes overdose awareness. She’s a “tough mother” fighting against fentanyl. Her first-born son Trevor died when he was only 18 years old in his dorm room, after taking what he believed to be an oxycodone pill that was, unbeknownst to him, laced with fentanyl. Leopold…

  • New study highlights opioid overdose risk following release from Oregon prisons

    By Sheraz Sadiq (OPB) In Oregon, people released from prison were 10 times more likely to overdose on opioids compared to the general population, according to a new study that tracked prison release and overdose data from 2014 to 2018. The risk of overdose doubled during the first two weeks of release, and formerly incarcerated women were…

  • SAMHSA Applauds Expansion of Access to Medication for Opioid Use Disorder (MOUD)

    The Substance Abuse and Mental Health Services Administration (SAMHSA) applauds provisions included in the 2023 Consolidated Appropriations Act (P.L. 117-328) that will significantly expand access to medication for opioid use disorder (MOUD). The act, signed into law by President Biden on Dec. 29, 2022, amended the Controlled Substances Act to eliminate the requirement for qualified…

Leave a Reply

Your email address will not be published. Required fields are marked *